The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Yevgeniy Balagula, Steven T. Rosen, Mario E. Lacouture

Research output: Contribution to journalReview articlepeer-review

57 Scopus citations

Abstract

Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.

Original languageEnglish (US)
Pages (from-to)624-635
Number of pages12
JournalJournal of the American Academy of Dermatology
Volume65
Issue number3
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Keywords

  • CIA
  • EGFR
  • EGFRI
  • FDA
  • Food and Drug Administration
  • HFS
  • HFSR
  • MASCC
  • Multinational Association for Supportive Care in Cancer
  • QoL
  • RCT
  • chemotherapy-induced alopecia
  • epidermal growth factor receptor
  • epidermal growth factor receptor inhibitor
  • hand-foot skin reaction
  • hand-foot syndrome
  • quality of life
  • randomized controlled trial

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies'. Together they form a unique fingerprint.

Cite this